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Abstract
Cell death and removal of cell corpses in a timely manner is a key event in both physiological and pathological
situations including tissue homeostasis and the resolution of inflammation. Phagocytic clearance of cells dying by
apoptosis is a complex sequential process comprising attraction, recognition, tethering, signalling and ultimately
phagocytosis and degradation of cell corpses. A wide range of molecules acting as apoptotic cell-associated ligands,
phagocyte-associated receptors or soluble bridging molecules have been implicated within this process. The role of
myeloid cell CD14 in mediating apoptotic cell interactions with macrophages has long been known though key
molecules and residues involved have not been defined. Here we sought to further dissect the function of CD14 in
apoptotic cell clearance. A novel panel of THP-1 cell-derived phagocytes was employed to demonstrate that CD14
mediates effective apoptotic cell interactions with macrophages in the absence of detectable TLR4 whilst binding and
responsiveness to LPS requires TLR4. Using a targeted series of CD14 point mutants expressed in non-myeloid cells
we reveal CD14 residue 11 as key in the binding of apoptotic cells whilst other residues are reported as key for LPS
binding. Importantly we note that expression of CD14 in non-myeloid cells confers the ability to bind rapidly to
apoptotic cells. Analysis of a panel of epithelial cells reveals that a number naturally express CD14 and that this is
competent to mediate apoptotic cell clearance. Taken together these data suggest that CD14 relies on residue 11 for
apoptotic cell tethering and it may be an important tethering molecule on so called ‘non-professional’ phagocytes thus
contributing to apoptotic cell clearance in a non-myeloid setting. Furthermore these data establish CD14 as a rapid-
acting tethering molecule, expressed in monocytes, which may thus confer responsiveness of circulating monocytes
to apoptotic cell derived material.
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Introduction
The essential feature of apoptosis in vivo is the highly
orchestrated clearance of dying cells by phagocytes. This
complex multistage process comprises attraction to and
recognition, tethering and phagocytosis of cell corpses, and is
the net result of the acquisition of neo-antigens (with the most
widely characterised example being the exposure of the
phospholipid phosphatidylserine [1]) and the loss of inhibitory
signals (e.g. CD31 [2] and CD47 [3]) at the dying cell surface.
Apoptotic cells (AC) are phagocytosed by local, viable
neighbouring cells and it has been suggested that a majority of
cell deaths in vivo may be cleared by such ‘amateur’
phagocytes. However, when the level of cell death exceeds
local corpse-clearance capacity (e.g. in lymphoid follicles [4],
acute inflammatory sites [5] or some tumours [6]) professional
phagocytes (i.e. macrophages) are recruited by dying cells
[7–10] to scavenge persisting dead and dying cells [11]. Most
human research in the field has addressed ‘professional’
clearance of AC by macrophages due to the importance in
resolution of acute inflammation and during development
[12–16]. However AC clearance by non-professional
phagocytes (e.g. endothelial/epithelial cells) is well established
though our knowledge and understanding of the mechanisms
involved is relatively sparse [17–22].
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Removal of AC utilises a range of phagocyte receptors that
bind, directly or indirectly (via soluble opsonic molecules), to
AC and function in a phagocytic synapse (reviewed
[6,11,13,23]). Many of these receptors and soluble opsonins
are components of the innate immune system (e.g. CD14,
complement components, collectins and pentraxins) i.e. are
pattern recognition receptors (PRR) - receptors proposed to
bind conserved molecular structures on microbes (pathogen-
associated molecular patterns, PAMPs e.g. LPS) to activate
immune responses [24]. Consequently it has been suggested
that AC bear PAMP-like structures named ‘apoptotic cell-
associated molecular patterns’ (ACAMPs) that are ligands for
PRR (e.g. CD14) mediating AC clearance [25,26]. In support of
this, LPS-like structures have recently been revealed on cells
undergoing apoptosis [27].
The most striking difference between PRR ligation by
PAMPs or ACAMPs lies in the cellular responses. CD14 binds
LPS to generate pro-inflammatory responses [28] whilst CD14
promotes AC binding and clearance in vitro and in vivo in a
non-inflammatory manner [29,30]. Thus CD14 ligation with
different ligands (PAMP or ACAMP) leads to opposing
responses and the molecular basis for this is yet to be defined
though a number of models have been proposed [11]. Early
mAb studies provide preliminary evidence that LPS and AC
may bind to similar regions of CD14 [29]. However AC binding
to CD14 remains to be finely mapped and differential ligation of
CD14 may underlie the important divergent responses to LPS
(pro-inflammatory) or AC (anti-inflammatory). Here we address
the key residues of CD14 involved in ligation.
CD14 is an established pro-inflammatory receptor for LPS
[31] and other microbial ligands (reviewed [32]) through
functional associations with signalling partners such as TLR4/
MD2. We hypothesised PAMPs and ACAMPs yield opposing
CD14-dependent responses through distinct modes of CD14
ligation thus effecting altered signalling. To this end we have
sought to more fully define CD14’s role on monocytes/
macrophages and more closely map AC-CD14 binding through
a series of targeted point mutants that span the region of CD14
containing LPS binding and signalling sites [33–36] and the
region for TLR association [37]. Furthermore we have sought to
compare the impact of these mutations on LPS and AC binding
and downstream responses.
CD14, a GPI-anchored glycoprotein [38,39] abundant on
monocytes and neutrophils, has been used as a marker of
monocyte/macrophage lineage, and is considered a myeloid-
restricted molecule (reviewed [40]). However we demonstrate
CD14 on non-myeloid cells and here characterise CD14 on
non-myeloid cells which we report promotes rapid tethering of
AC by so called ‘non-professional’ phagocytes thus providing
valuable insight to mechanisms by which amateur phagocytes
may clear AC.
Materials and Methods
Cell lines and culture
All cells were cultured at 37°C in a humidified environment at
5% CO2. Mutu I Burkitt’s lymphoma (BL) cells [29,41], U937
(human monocyte line; ATCC) and THP-1 (human
myelomonocytic line; LGC Standards-ATCC, Middlesex, UK)
were cultured in RPMI 1640 medium. BEAS-2B (normal human
bronchial epithelial cells; LGC Standards-ATCC), HEK-293
(human kidney epithelial line; LGC Standards-ATCC), HeLa
229 (human cervical epithelial line; LGC Standards-ATCC),
and MCF-7 (human mammary epithelial line; LGC Standards-
ATCC) were cultured in DMEM (PAA, Yeovil, UK); Calu-3
(human airway epithelial line; LGC Standards-ATCC) and H400
(human oral epithelial line [42]) were cultured in DMEM/F12
whilst Human Pulmonary fibroblasts isolated from human lung
(PromoCell GmbH, Heidelberg, Germany) were cultured in
HPFM (PromoCell). All media were supplemented with 2 mM L-
glutamine and 10% (v/v) foetal calf serum and 100 IU ml-1
penicillin and 100 µg ml-1 streptomycin (PAA).
THP-1 cells were stimulated to differentiate towards a
macrophage phenotype by 48-72h treatment with 100nM
dihydroxyvitamin D3 (VD3; Biomol, Exeter, UK), 250nM
phorbol ester (PMA, Sigma, Dorset, UK) or both reagents
(VD3/PMA).
Antibodies
Anti-CD14 monoclonal antibodies 61D3 and 63D3 were
obtained as described previously [41] and were produced as
tissue culture supernatants whilst MEM18 was purchased
(azide-free) from Abcam (Cambridge, UK). All CD14 mAbs
were of the isotype IgG1/κ and consequently MOPC21 (Sigma)
was used as an isotype matched control. Anti-TLR 4 mAb
(HTA125) was supplied unconjugated or as a phycoerythrin-
conjugate and matched isotype controls (IgG2a/κ) were
supplied by Abcam. Goat anti-mouse secondary reagents used
for indirect immunofluorescence studies were used with PE
conjugates (Sigma). Sheep anti-mouse-HRP was used for
ELISA studies and was supplied by GE Healthcare Life
Sciences (Little Chalfont, UK). Sheep anti-human Fc polyclonal
antibody was supplied by The Binding Site (Birmingham, UK).
Recombinant protein expression and analysis
Soluble CD14 expression constructs were generated as
previously described [43] to encode CD14 (wild type or point
mutant) fused to Fc of human IgG1. These constructs were
sub-cloned into a full-length GPI-anchored form by Hind III/
NheI excising the 5’ coding region (containing any desired point
mutant) and ligating into a similarly cut full length CD14
construct in pcDNA3. The result was a full length CD14
molecule containing the desired point mutants. All mutations
were confirmed by sequencing. Soluble CD14-Fc proteins were
produced in HEK cells followed TransIT-LT1 (Mirusbio,
supplied by Geneflow, Lichfield, UK) mediated cDNA transient
transfection as per the manufacturer’s instructions. At 24h post-
transfection, medium was replaced with serum-free DMEM and
following a further 72 h expressed protein secreted to the
supernatant was used directly. For expression of GPI-anchored
CD14, TransIT-LT1 mediated transient transfection was again
used in the indicated cell lines as per manufacturer’s
instructions.
Soluble CD14-Fc constructs were assayed by ELISA.
Nunclon Maxisorp 96 well plates (Thermo, Fisher Scientific,
Loughborough, UK) were coated with sheep-anti-human at
CD14 and rapid tethering of apoptotic cells
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e70691
5µg/ml in carbonate buffer (pH 9.6; Sigma, Dorset, UK).
Following washing with PBS(T) (PBS + 0.05% v/v Tween 20),
expressed Fc-tagged CD14 proteins were added directly in
tissue culture supernatants. The resultant, captured and
oriented Fc-fusions were probed with mAbs and bound mAb
detected using anti-mouse-HRP and colorimetric SigmaFAST
OPD assay (Sigma). In order to control for differing levels of
protein production, binding of mAbs was expressed relative to
binding of mAb 63D3 whose binding is unaffected by mutation
as it binds to the C terminus of CD14 [44,45].
For indirect immuno-fluorescence of cells expressing
membrane anchored CD14 constructs (wild type and point
mutants), an excess of mAb was incubated with 200,000 cells
on ice for 15-30 min, washed in 0.5% (w/v) BSA in PBS and
incubated with goat-anti mouse conjugated to PE (1/100
dilution; 100µl volume). Stained cells were analysed either
directly or following fixation in 1% w/v formaldehyde in PBS
using a Beckman-Coulter Quanta SC. Downstream flow
cytometric analyses and presentations were undertaken using
FlowJo (Treestar Inc., Oregon, USA).
Apoptosis induction, detection and photomicroscopy
Mutu I (Burkitt’s lymphoma cells) were exposed to 100
mJ/cm2 UV–B irradiation, using a Chromata-vue C71 light box
and UVX radiometer (UV–P Inc, USA), and incubated for 16h
to allow apoptosis to proceed [10]. For analysis of apoptotic
nuclear morphology, cells were fixed in 1% w/v formaldehyde
in PBS, stained with 4,6-diamidino-2-phenylindole (DAPI,
Sigma, 250ng/ml) and observed using inverted epifluorescence
microscopy. For morphological studies, THP-1 cells were
seeded to 4 well Lab-Tek II Chamber slides with a coverglass
bottom (Thermo, Fisher Scientific) and stimulated to
differentiate for 48 hours prior to microscopy. DIC imaging with
a 63x (1.4 numerical aperture) Zeiss objective was used for
morphology. Nuclei were imaged following acridine orange
staining (Sigma, 5µg/ml final concentration). All
photomicrography was undertaken using a fully motorised
Zeiss Axiovert 200M fluorescence microscope (Carl Zeiss Ltd.,
Welwyn Garden City, UK) and Hamamatsu Orca camera driven
by Volocity (PerkinElmer, Cambridge, UK).
Apoptotic cell-phagocyte interaction assays
Tethering of AC to phagocytes or interaction (tethering and
phagocytosis) of AC with phagocytes was assayed as
previously described [46]. Briefly, phagocytes (THP-1-derived
or epithelial cells) were seeded to multi-well glass slides [29]
and co-cultured with AC (106 per well) for 1hr at 37°C
(interaction) or 4°C (tethering) in RPMI containing 0.2% (w/v)
bovine serum albumin (Sigma) in the presence or absence of
mAbs (1:10 dilution) as appropriate to the experiment. The anti-
CD14 mAb 61D3 was used to block CD14-dependent AC
interactions with the non-blocking anti-CD14 mAb 63D3 used
as a control [29]. Unbound cells were removed by extensive
washing and slides fixed in methanol, stained with Jenner/
Giemsa (Thermo, Fisher Scientific) and mounted in DPX
(Thermo, Fisher Scientific) prior to examination by light
microscopy. Binding was undertaken at reduced temperatures,
as indicated, with pre-cooled solutions and cell suspensions. In
all cases at least 200 macrophages were assessed in each of
quadruplicate wells. Data are presented as the percentage of
phagocytes binding or interacting with AC. Where transfected
HeLa cells were used as phagocytes, cells were reseeded to 4
well glass slides at 24h post-transfection and allowed to stick
and spread for 18h prior to use.
Assays of cell responses to LPS
LPS from E. coli O111:B4 (Sigma) was applied to cells
(THP-1-derived macrophage cells or epithelial cells (including
transfectants) in 24 well plates in the presence of 10% normal
human serum (Sigma) as a source of LPS-binding protein.
Following indicated time-periods, tissue culture supernatants
were harvested and analysed by ELISA for secreted cytokines
TNF-α (R&D systems, Abingdon, UK) or IL-8 (Peprotech EC
Ltd., London, UK).
In order to specifically assess NFκB transcriptional activity, a
luciferase-based NFκB reporter construct (pGL4.32 NFκB
reporter; Promega, Southampton, UK) was co-transfected
transiently into HeLa cells using TransIT-LT1. Following cell
stimulation with LPS or experimental treatments, luciferase
activity using One-Glo (Promega) was quantified using an
Orion II microplate luminometer (Berthold Detection Systems,
Pforzheim, Germany).
Statistical Analysis
Statistical analysis of results was undertaken using one-way
analysis of variance (ANOVA) with a post-test as appropriate to
the experiment. All analyses were based on a minimum of
three independent experiments and were undertaken using
InStat (GraphPad, La Jolla, CA, USA).
Results
Expression and function of CD14 on undifferentiated
and differentiated THP-1 cells
CD14 expression on myeloid cells (e.g. monocytes,
macrophages and neutrophils) is well established though
characterisation of function has been largely limited to LPS-
induced cytokine responses. We have made significant use of
the human monocyte line THP-1 as a source of differentiated
myeloid-derived cells expressing CD14. Our initial studies
sought to characterise this new panel of macrophage model
cells with respect to cell phenotype and function in tethering
and mediating responses to AC and LPS with specific
relevance to CD14.
Treatment of THP cells with dihydroxyvitamin D3 (VD3),
PMA or both (VD3/PMA) yields three distinct macrophage-like
cells when analysed for phenotype and function. Treatment
with VD3 alone had no detectable effect on cell volume,
granularity or cell division suggesting little stimulation of THP
cells from their basal monocyte phenotype whilst treatment with
PMA or VD3/PMA had profound effects with increased cell
volume (Figure S1A) and reduced cell number after 72h
stimulation (Figure S1B). Additionally, only THP-PMA or THP-
VD3/PMA showed increased adhesion to plastic (assessed by
ease of cell lifting with EDTA treatment: data not shown) with
CD14 and rapid tethering of apoptotic cells
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profound morphological changes, suggesting a more
advanced, macrophage-like phenotype (Figure S1C). Notably,
the different models possessed a range of CD14 expression
profiles (Figure 1A) with THP-VD3 cells expressing highest
levels of CD14, clearly demonstrating differentiation despite
little morphological change. These results revealed an
opportunity to assess if CD14 handles AC and LPS in a distinct
manner that might underlie divergent cell responses to these
ligands. Thus here we describe a powerful range of cell types
that are amenable to a range of high-throughput and high-
content assays.
To assess LPS sensitivity, TNF-α production in response to a
range of LPS concentrations was assayed for each model
system and revealed profoundly different responses (Figure
1B) that did not directly correlate with CD14 expression (Figure
1A). Whilst THP-VD3 expressed most CD14 they were not so
responsive as THP-VD3/PMA or THP-PMA cells. Further
analysis of TLR-4, the well-established LPS-receptor with
which CD14 cooperates for the efficient response to LPS,
indicates that the greatest LPS-responsiveness correlated with
the highest TLR-4 expression (Figure 1C). These data suggest
that high CD14 expression is not sufficient for, and high TLR-4
surface expression is not essential for, strong LPS responses.
Thus these different model systems provide a valuable
opportunity to assess the roles of CD14 and TLR-4 in tethering
of and responses to AC.
To assess the ability of these different macrophage-like cells
to interact with AC, differentiated THP-1 cells were co-cultured
with AC and the level of phagocyte-AC interaction quantified.
Our studies indicate that all three cell types are capable of
interacting with AC to a similar degree (Figure 2A) and they did
not display the variation noted with LPS responses (Figure 1).
We further sought to address CD14’s contribution to AC
interaction in each cell systems through the use of the well-
established CD14 inhibitory mAb 61D3 and its non-inhibitory
counterpart 63D3 [29,41]. In each case CD14 was involved
(Figure 2B) in AC-phagocyte interaction with the involvement
most profound in THP-VD3 and THP-PMA (Figure 2C), cells
that exhibit dramatically different CD14 expression levels
(Figure 1A). These data demonstrate CD14 is most active for
AC interaction in those cells (VD3 or PMA) where, irrespective
of absolute CD14 expression, TLR-4 expression was lowest
(i.e. with limited or undetectable TLR-4). This suggests low
levels of CD14 are sufficient for AC interaction and TLR-4 is
not necessary for CD14-dependent clearance of AC. Indeed,
the involvement of CD14 in AC clearance negatively correlates
with TLR-4 surface expression.
Thus these data may suggest a key difference in the
generation of cell responses elicited following CD14 ligation.
We further sought to address the ability of each of these THP-1
model systems to elicit an inflammatory response to LPS and
for this to be attenuated by AC. In all cases AC reduced the
inflammatory response (Figure 3) irrespective of CD14 and
TLR-4 expression or LPS-responsiveness.
Figure 1.  Characterisation of THP-1 macrophage
phenotype and LPS responses.  THP-1 monocytes (THP-1)
cells were stimulated to differentiate in the presence of
dihydroxyvitamin D3 (VD3), phorbol ester (PMA) or both (VD3/
PMA) for 72 hours prior to analyses. (A) Flow cytometric
analysis of cell surface CD14 expression using indirect
immunofluorescence with mAb 63D3 detected with anti-mouse-
phycoerythrin. Frequency histograms of at least 5000 events
are shown for each cell type (open black: CD14; solid grey:
IgG1/κ isotype control). Data shown are representative of at
least three independent experiments. (B) Production of TNF-α
in response to a range of LPS concentrations for 4h in the
presence of 10% v/v normal human serum, detected by ELISA
(data shown are mean ± SE for 3 independent experiments).
(C) Flow cytometric analysis of cell surface TLR-4 using direct
immunofluorescence with mAb HTA-125-phycoerythrin (open
black: anti-TLR-4; solid grey: IgG2a/κ isotype control). Data
shown are representative of at least three independent
experiments.
doi: 10.1371/journal.pone.0070691.g001
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Figure 2.  All THP-1 cell-derived macrophages utilise CD14
for interaction with apoptotic cells.  UV-induced apoptotic
BL cells (>80% apoptotic as assessed by nuclear morphology)
were co-cultured with THP-1 phagocytes in the presence of the
indicated mAbs (anti-CD14 mAb 61D3, a blocking CD14 mAb,
or anti-CD14 mAb 63D3, a non-blocking, isotype matched
control). Following co-culture (1h) at 37°C unbound apoptotic
cells were removed and the interaction of phagocytes with
apoptotic cells assessed by light microscopy of Jenner-Giemsa
stained cells. (A) shows the percentage of phagocytes
interacting with apoptotic cells. (B) shows the effect of 61D3
and 63D3 on apoptotic cell interaction with phagocytes (% of
AC alone). (C) Compares the 61D3 inhibition as a measure of
CD14 function for each macrophage type. All data shown are
mean ± SE for 7 independent experiments. Statistical analyses
used ANOVA with Bonferroni post test. *P<0.05; **P<0.01;
***P<0.001.
doi: 10.1371/journal.pone.0070691.g002
Different anti-CD14 mAbs that block AC clearance bind
distinct residues in CD14
To closely map CD14 residues involved in AC handling, a
series of CD14 point mutants (used previously to analyse the
binding of labelled LPS [43]) were used to characterise the
interaction with AC. This work was thus designed to address
the hypothesis that the divergence of phagocyte responses to
CD14 ligation by LPS or AC arises from the key residues
involved being different.
Previous work shows mAbs 61D3 and MEM18 compete for
CD14 binding suggesting epitope similarity [29,47] and both
mAbs block AC tethering, suggesting their potential use as
surrogate markers of AC binding to CD14. Here we extend
those studies to screen mAb binding (by ELISA) to a panel of
soluble CD14-Fc (sCD14-Fc) point mutants that span the N-
terminal 60 amino acids of CD14 known to be essential for LPS
binding and signalling sites. Binding of non-blocking mAb 63D3
was unaffected by any mutation, consistent with it binding
CD14’s C-terminus [44,45] and thus confirmed equivalent
expression of these mutants (Figure S2A). However, binding of
Figure 3.  THP-1 macrophage responses to LPS in the
presence of apoptotic cells.  THP-1 cells or THP-1-derived
macrophages (VD3, PMA or VD3/PMA differentiated) were co-
cultured with UV-induced apoptotic human B cells for 18h prior
to stimulation with LPS. Following 4h stimulation, supernatants
were assayed for TNF-α by ELISA. Data presented are TNF-α
produced in the presence of LPS and apoptotic cells (LPS+AC)
as a percentage of that produced with LPS alone (i.e. no AC
added) for each cell type. Data shown are mean ± SE of four
independent experiments. Statistical analyses used ANOVA
with Bonferroni post-test. **P<0.01; ***P<0.001.
doi: 10.1371/journal.pone.0070691.g003
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61D3 (but not MEM18) was significantly reduced by
replacement of residue 11 with a neutral or positively-charged
residue suggesting a negative charge is required at this site for
61D3 binding (Figure 4A). Additionally mutation of residue 37
showed partial inhibition of 61D3 binding. Consistent with
previous work, mutation of residue 59 inhibited binding of
MEM18 [33,36] (Figure 4A, right panel) but not 61D3. Thus
these two mAbs that both block LPS responses and AC
clearance exhibit profoundly different binding patterns to CD14.
To exclude the possibility that these results were soluble
CD14-specific, similar mapping studies were undertaken using
membrane CD14 (mCD14: WT and mutants) expressed in
HeLa cells (chosen for their strong adhesion, ease of
transfection and, for later experiments, low basal AC tethering).
Binding of mAbs 61D3 and 63D3 to mCD14 mutants was
assessed via immunofluorescence and flow cytometry (Figure
4B). Equivalent binding of 63D3 to all mCD14 constructs
revealed robust mCD14 expression in a characteristic bi-modal
distribution (Figure 4B). Similar mapping was undertaken with
MEM18 (Figure 4C). Consistent with our sCD14 mAb mapping,
these cell-based assays revealed 61D3 (but not MEM18)
binding was profoundly inhibited by residue 11 mutation whilst
Figure 4.  Mapping of key residues within CD14 that are required for binding of mAbs 61D3 and MEM18.  Monoclonal Abs
61D3 and MEM18 were tested for reactivity against wild-type CD14 and a panel of point mutants. (A) Anti-human Fc immobilised
soluble CD14-Fc fusion proteins were probed by ELISA with 61D3 or MEM18 and mAb binding detected with anti-mouse-HRP prior
to developing with OPD substrate and reading OD492nm. mAb is shown as a ratio of 63D3 binding to control for protein expression.
Data shown are mean ± SE of three independent experiments and mAb (61D3 or MEM18) binding (relative to 63D3) is expressed
as a % of binding to wtCD14Fc. Statistical analysis conducted was ANOVA followed by Dunnett’s post-test (**P<0.01 compared to
wtCD14). (B) HeLa cells were transfected with the indicated membrane CD14 (WT or mutant) prior to staining with IgG1/κ isotype
control MOPC21, anti-CD14 mAb 63D3, or (C) anti-CD14 mAb MEM18. In each case, mAb binding was detected using goat anti-
mouse-PE and flow cytometry. Fluorescence data are shown as histograms with at least 5000 events per plot and are
representative of at least three independent experiments.
doi: 10.1371/journal.pone.0070691.g004
CD14 and rapid tethering of apoptotic cells
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MEM18 (but not 61D3) binding was inhibited by mutation of
residue 59. Regression studies indicate that 61D3-CD14
binding (WT or mutant) was similar for sCD14 and mCD14
(Figure S2C: correlation coefficient r2=0.82).
Despite these clear differences in key residues for 61D3 and
MEM18 binding previous work [29], repeated here (Figure S3)
has indicated that mAbs 61D3 and MEM18 compete for CD14
binding suggesting close proximity of their epitopes and thus
residues 11 and 59. This is further supported by the functional
observations that both mAbs block AC binding.
CD14 residue 11 is essential for apoptotic cell binding
Extending our CD14 mutant mapping studies from the use of
mAbs as surrogate markers of AC binding, we sought to map
AC binding to our panel of CD14 constructs. Use of soluble
CD14 mutants was not possible due to the inherent variability
noted between binding experiments. Hence, mCD14 constructs
were screened using HeLa cells transiently transfected with
mCD14 and an assay was developed that made use of low-
temperature to prevent phagocytosis whilst permitting tethering
to proceed. To assess CD14 function in this system, we
established an assay system that revealed improved AC
tethering following wt-mCD14 expression (akin to previous non-
human systems [29]). Following extensive work an assay was
optimised that assessed AC tethering to phagocytes in a 5
minute co-culture at 4°C. This assay demonstrated CD14’s
ability to significantly improve AC tethering capacity of non-
professional phagocytes by 100% (Figure 5A). Extended
periods (15 minutes+) showed higher levels of AC tethering
that masked CD14’s function (Figure 5A), presumably as other
redundant receptors came into play. This suggests CD14 is a
key molecule in the rapid, earliest binding events of
professional phagocytes and may have important implications
for the function of circulating monocytes responding to material
released from AC (e.g. from sites of apoptosis such as tumours
and atherosclerotic plaques).
Using this developed assay system, mCD14 constructs (WT
and mutant) were transiently expressed in HeLa cells and
CD14 expression assessed using mAb 63D3, known to bind
away from the mutated regions [44,45]. Flow cytometric
analysis demonstrated successful, equivalent expression of all
mCD14 mutants (Figure S2B shows representative expression
data). The characteristic bi-modal expression distribution (e.g.
Figure 4B Figure S2B) was noted in all cases and also with
control transfection with a reporter GFP plasmid suggesting
this is a feature of HeLa cell transfection rather than a CD14-
specific effect.
Results from AC tethering to these HeLa/mCD14 cells are
shown (Figure 5B). We demonstrate that glutamic acid at
residue 11 (key for 61D3 binding) was also a key residue for
AC tethering. Importantly this mutation does not destroy the
overall confirmation of CD14 as all other mAbs tested bind well.
Also residue 59 (important for MEM18 binding) was mutated
without altering the ability of CD14 to mediate AC tethering.
Thus we believe 61D3 to be a good surrogate marker of AC
binding and for residue 11 to be key for tethering of AC by
CD14.
Figure 5.  Residue 11 of CD14 is essential for binding to
apoptotic cells.  HeLa cells were used as surrogate
phagocytes and co-cultured with apoptotic human B cells.
Following co-culture at 4°C unbound apoptotic cells were
removed and the interaction of phagocytes with apoptotic cells
assessed by light microscopy of Jenner-Giemsa stained cells.
(A) HeLa cells (mock or CD14WT transfected) co-cultured with
UV-induced apoptotic human B cells (>80% apoptotic as
assessed by nuclear morphology) for 5 or 15 min were used to
assess the optimal period to reveal the role of CD14 to promote
apoptotic cell binding. Data shown are mean ± SE for three
independent experiments. Statistical analyses used ANOVA
with Tukey post-test. **P<0.01. (B) HeLa cells transfected with
CD14WT or point mutants were used as surrogate phagocytes
and co-cultured with apoptotic human B cells for 5 min.
Following co-culture at 4°C unbound apoptotic cells were
removed and the interaction of phagocytes with apoptotic cells
assessed by light microscopy of Jenner-Giemsa stained cells.
Data are shown as the percentage of HeLa cells interacting
with apoptotic cells (mean ± SE above the binding to HeLa
mock) for three independent experiments. Statistical analyses
used ANOVA with Dunnett’s post-test. *P<0.05; **P<0.01.
doi: 10.1371/journal.pone.0070691.g005
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CD14-mediated responses
Divergent responses emanating from CD14 ligation may be
due to alternative ligation of CD14 by different ligands. To this
point, our data support the notion that AC and LPS ligate CD14
using at least some similar residues. Consequently, one might
predict pro-inflammatory signalling to occur following LPS or
AC binding to CD14 and this signalling be inhibited
downstream. To test this, we used an NFκB reporter in HeLa/
mCD14 cells to report pro-inflammatory transcriptional
activation. Initial work titrated LPS on HeLa/CD14 cells versus
HeLa/mock transfected cells to ascertain the minimum LPS
concentration that would induce a significant CD14-dependent
response to LPS (Figure S4). This LPS concentration
(100µg/ml) was thus used for future experiments. We note
strong LPS-induced transcriptional activation when CD14 is
expressed, confirming inflammatory signalling (Figure 6B).
However, AC fail to induce detectable NFκB-dependent
transcription in HeLa/CD14 cells above background,
suggesting ligation of CD14 by AC does not activate NFκB
responses. Of interest though is the observation that AC
reduce the baseline response in HeLa/mock cells, suggesting
AC are capable of modulating NFκB responses by a CD14-
independent mechanism.
Non-myeloid CD14 mediates apoptotic cell clearance
Our data in HeLa cells suggest strongly that CD14 is a rapid-
acting tethering receptor for AC. Whilst screening a panel of
epithelial cells as candidates for our CD14 over-expression
studies (above) we noted CD14 expression on two pulmonary
epithelial cells, BEAS-2B and Calu-3, but not on other epithelial
cells or pulmonary fibroblasts tested (Figure 7A) providing a
valuable opportunity to assess the function of natural
expressed CD14 on non-myeloid, ‘amateur’ phagocytes. Whilst
mCD14 is often considered to be myeloid-restricted, a number
of studies challenge this (reviewed [40]). In our studies,
BEAS-2B expressed robust levels of mCD14 consistent with
the cell’s ability to respond to LPS in a dose-dependent manner
for the production of IL-8. Calu-3 cells expressed much lower
levels of CD14 and were less LPS-responsiveness. Despite
expression of CD14 on these cells they were relatively weakly
LPS-responsive (Figure 7B in comparison to myeloid cells
Figure 1) and this is likely due to the low/negative levels of
detectable TLR-4 at the cell surface (Figure 7C).
We further sought to assess, for the first time, the ability of
epithelial cell-expressed CD14 to mediate interaction with AC
using mAb 61D3 as a tool to block CD14’s AC tethering
function. These studies reveal that Beas-2B and Calu-3 both
interact with AC in a CD14-dependent manner whilst other cells
tested (with no detectable mCD14) did not (Figure 8). The
extent of CD14 involvement is significant in both BEAS-2B and
Calu-3, even when CD14 expression levels are relatively low,
consistent with CD14 playing an important role for tethering
AC.
Taken together these data may suggest CD14 on pulmonary
epithelial cells primarily promotes AC clearance within the
lungs and that poor TLR-4 expression is a safe-guard against
chronic stimulation from the lung microbiome [48]. The
presence of CD14 on pulmonary epithelial cells may thus
Figure 6.  LPS but not apoptotic cells activates NFκB
inflammatory signalling.  HeLa cells were transfected with
both the luciferase NFκB reporter plasmid and a CD14WT
expression plasmid or ICAM-3 expression plasmid as a control
using TransIT LT-1. Expression was allowed to proceed for 24
hours prior to further analyses. (A) CD14 expression was
assessed using indirect immunofluorescence with mAb 63D3
(open black) detected using goat anti-mouse PE, compared to
isotype control stained cells (solid grey). (B) Cells were treated
with either 100µg/ml of LPS or apoptotic human B cells for 5h
prior to assessing NFκB-mediated transcriptional activity with
One-Glo Luciferase assay system. Apoptotic cells were in
excess of 80% apoptotic by nuclear morphology. Relative light
units were quantified using a microplate luminometer. The data
shown is mean ± SE of three independent experiments.
Statistical analyses used ANOVA with Tukey post-test.
**P<0.001; ***P<0.001; ns = not significant.
doi: 10.1371/journal.pone.0070691.g006
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Figure 7.  CD14 is expressed in non-myeloid cells but is
not sufficient for inducible LPS responses.  (A) Flow
cytometric analysis of cell surface CD14 expression on a panel
of non-myeloid cells. Cells were assessed for cell surface
CD14 through the use indirect immunofluorescence with anti-
CD14 mAb 63D3 (or MOPC21 isotype control) and detected
with goat anti-mouse-phycoerythrin. Frequency histograms of
at least 5000 events are shown for each cell type (red: CD14;
grey: IgG1/κ isotype control). Numerical values shown are the
mean fluorescence intensity for anti-CD14 (open black) or
isotype control (solid grey) stained cells. (B) IL-8 production by
CD14-expressing BEAS-2B and Calu-3 cells following LPS
treatment at the indicated concentrations for 24 hours. ELISA
of supernatant IL-8 was undertaken and results shown are
mean ± SE of three independent experiments. (C) Flow
cytometric analysis of cell surface TLR4 expression on
BEAS-2B and Calu-3 cells. Cells were assessed for cell
surface TLR4 by direct immunofluorescence with PE-
conjugated anti-TLR4 mAb HTA125 (or an isotype control).
Frequency histograms of at least 5000 events are shown for
each cell type (open black: TLR4-PE; solid grey: IgG2a/κ
isotype control-PE). Values shown are the mean fluorescence
intensity for anti-TLR4 (black) or isotype control (grey) stained
cells.
doi: 10.1371/journal.pone.0070691.g007
promote immobilisation of AC and debris until efficient
phagocytosis can occur. Furthermore this may be critical in
influencing airways inflammation [42]. Further work is required
to establish fully the significance of these CD14 observations.
Discussion
Whilst previous studies suggest CD14 mediates both LPS-
induced inflammation and AC tethering via closely associated
regions, the precise residues involved in binding of PAMPs/
ACAMPs have not been resolved despite the potential
importance in generating opposed cell responses. Herein we
characterise CD14’s role in AC tethering and cellular
responses through the use of a series of CD14-expressing
myeloid and non-myeloid model systems.
We report four different myeloid cell systems (THP-1 cells
and three macrophage derivatives with differing levels of CD14
and TLR4) and show, for the first time, markedly different
macrophage responses to LPS though similar AC clearance
capacity. Whilst CD14 levels do not correlate with the cells’
ability to clear AC (Figures 1 and 2), the most LPS-responsive
cells (THP-VD3/PMA) utilise CD14 the least to tether AC
Figure 8.  Extramyeloid CD14 is functional to mediate
interaction with apoptotic cells.  Non-myeloid cells (epithelial
cells: BEAS-2B, Calu-3, H400, MCF-7 HeLa or human
pulmonary fibroblasts, HPF) were seeded to glass slides and
co-cultured with apoptotic human B cells in the absence or
presence of anti-CD14 mAbs 61D3 or 63D3. Following co-
culture for 1h at 37°C, unbound apoptotic cells were removed
by washing and the percentage of non-myeloid phagocytes
interacting with apoptotic cells was assessed by light
microscopy of Jenner-Giemsa stained cells. Results shown are
mean ± SE of three independent experiments. Statistical
analyses used ANOVA with Tukey post-test. *P<0.05;
**P<0.01.
doi: 10.1371/journal.pone.0070691.g008
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(Figure 2C). Furthermore, those cells (THP-VD3; THP-PMA)
with lowest TLR-4 expression (irrespective of CD14 levels)
used CD14 to the greatest degree in tethering AC (Figure 2C).
Taken together these data suggest that TLR-4 expression
negatively correlates with CD14’s ability to tether AC, possibly
through competition for CD14 binding. This may help explain
why TLR-4-/- macrophages take up AC more efficiently than
TLR4+/+ macrophages [49]. Previous studies have addressed
TLR involvement in AC removal as PRRs are proposed to bind
ACAMPs - ligands that have recently been revealed on the
surface of AC [27]. However TLR4 is involved in phagosome
maturation rather than AC-tethering [49]. TLRs have also been
implicated in responses to necrotic cells [50] and thus AC may
exclude TLR4-MD2 from the CD14 signalling complex within
lipid rafts [51], a possible mechanism by which inflammatory
signalling from CD14 ligation may be reduced by AC. CD14
interacts with TLR4/MD2 in the presence of LPS, which is
sandwiched between CD14 and TLR4/MD2, to effect
inflammatory signalling [52]. Thus tethering of AC to CD14
residues required for LPS binding/signalling may outcompete
LPS and prevent TLR4 involvement [53].
A further explanation of how LPS and AC may ligate CD14
yet yield opposing responses lies in the precise residues
ligated. Here we show two mAbs (61D3 and MEM18), which
individually block both LPS responses and AC binding, bind
different key residues in CD14 with 61D3 reliant upon residue
E11 and MEM18 on residue D59. Given the similar functional
effects of these mAbs this may be surprising. However,
assuming good structural homology between mouse and
human CD14, the residues are topologically close when
mapped onto the predicted 3D crystal structure [54]. Within this
crystal structure, four previously identified regions essential for
LPS binding/signalling [33,34,36,43,55] have been identified
and E11 and D59 lie within these regions and are closely-
associated with the rim and wall of the LPS-binding pocket of
CD14 respectively [54].
Our analyses of mCD14 mutants in HeLa cells indicate that
AC tethering, in a novel and robust binding assay, is also
dependent on residue E11. Thus this work defines mAb 61D3
as a good surrogate marker for AC tethering by CD14. Our
studies suggest that a negative charge is essential at residue
11 for efficient AC binding. Notably, binding of mAb 61D3 to
CD14 is more sensitive to mutation in residue 11 than is AC
binding. Replacement of an acidic residue with either a basic or
neutral residue has profound effects on 61D3 binding. AC
binding is much less affected by a neutral substitution at this
site. This likely reflects the differences between mAbs and AC
as ligands, where AC have many other points if interaction with
HeLa cells whilst mAbs bind a single epitope on CD14. This
work identifies for the first time the crucial residue in CD14 that
is essential for CD14’s function to tether AC.
The precise residues involved in LPS binding are difficult to
define and mAb studies have been widely used, with MEM18
reported to compete with LPS for CD14 binding [33] though
single residue mutation studies do not reveal residue D59 as
essential for binding of E. coli LPS [43] with residues 37-44
implicated [36,55]. Notably region 1 of CD14, which includes
residue 11 that we show is essential for CD14 tethering of AC,
is not essential for LPS binding but is necessary for CD14-
dependent activation [34,56]. More detailed mutation studies,
incorporating single residue substitution mutations, also
demonstrate that residue 11 mutation does not affect binding of
E. coli LPS [43]. Thus it is possible that AC binding to residue
11 may inhibit LPS signalling and, via competition, also inhibit
LPS binding to other essential residues so as to reduce the
potential for LPS pro-inflammatory signalling.
Given our observation that a key signalling residue in CD14
is essential for AC tethering, it was possible that AC-CD14
binding was agonistic (i.e. pro-inflammatory). However we
demonstrate AC ligation does not stimulate NFκB pro-
inflammatory signalling. Thus if CD14 signalling, following AC
ligation, is activated, it is inhibited upstream of NFκB. Taking all
our data together, it seems most likely that AC prevent CD14
inflammatory signalling by modification of the signalling
complex at the cell surface, a possibility that requires further
study.
Of relevance to this discussion, is the identity of ligands for
CD14 that reside on AC. To date they have not been formally
identified though it has been suggested that apoptotic cell-
associated ICAM-3 may mediate AC removal through the
CD14 pathway [57]. Whilst this is an attractive possibility, there
is no evidence to indicate that CD14 and ICAM-3 directly
interact. Irrespective of this, CD14 is known to mediate removal
of apoptotic cells that do not express ICAM-3, suggesting that
other ligands likely exist [47]. AC-associated ligands for PRR
(e.g. CD14) have been suggested to share structural
similarities with PAMPs and thus be recognisable [25] [26].
Recently a novel strategy to identify ACAMPs has been used
successfully, through the use of anti-LPS mAbs. However,
whilst this epitope colocalised with annexin V- and C1q-binding
sires on AC, it did not appear to interact preferentially with
CD14 [27].
Finally whilst establishing our novel human AC tethering
assay, we identified airways epithelial cells that naturally
express CD14. This extra-myeloid CD14 expression has been
the subject of debate but has been reported on primary
epithelium from airways and urogenital tract (reviewed [40]).
Early studies have shown sCD14 and transfected mCD14
support LPS responses of non-myeloid cells (reviewed [32]).
Here we demonstrate that CD14 expressed in HeLa cells
significantly improve their ability to tether apoptotic cells in a
rapid manner, suggesting that CD14 functions apically in the
tethering process. This perhaps accounts for the profound
phenotype noted in CD14-/- mice where persisting AC are noted
in multiple tissues [46]. Furthermore, we demonstrate, for the
first time, that naturally occurring extra-myeloid CD14 is
functional for AC tethering. These data suggest that CD14’s
primary role in non-myeloid airway cells may be to immobilise
AC rapidly and, should the dead cell burden not be too great, to
also remove cell corpses. In support of this hypothesis,
increases in shed, soluble CD14 (e.g. by human neutrophil
elastase, which reduces clearance of AC [58]) is associated
with heightened airways inflammatory responses and an
increased burden of AC (e.g. in smoking-related emphysema
[59]; following allergen challenge of asthmatics [60]).
Additionally, reduced AC clearance is linked to lung disease in
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humans and, in rodent models, induction of apoptosis in the
airways leads to pathological changes typical of emphysema
(reviewed [61]). Interestingly the relatively poor inflammatory
responses of these cells to LPS may be functionally important
within the airways. The lungs do not constitute a sterile
environment and poor CD14 responses to LPS prevent chronic
inflammation in response to the LPS load of the lung
microbiome [48]. Furthermore a recent report highlights
apoptotic cell clearance by bronchial epithelial cells as a critical
influence on airway inflammation [42]. Thus the rapid tethering
of apoptotic cells mediated by non-myeloid CD14 may be an
important event in the control of pulmonary inflammation.
Supporting Information
Figure S1.  Morphological characterisation of THP cells
and their differentiated counterparts.  (A) THP-1 monocytes
(THP-1) cells were stimulated to differentiate in the presence of
dihydroxyvitamin D3 (VD3), phorbol ester (PMA) or both (VD3/
PMA) for 48 hours. Resultant cells were detached into 5mM
EDTA in PBS by incubation at 37°C for 15 min prior to flow
cytometric analysis of cell volume. Data shown are
representative of the electronic volume frequency histograms
for the resultant cell populations. (B) THP-1 cells were seeded
at a density of 5x105 cells per well prior to mock treatment
(THP-1) or treatment with 100nM dihydroxyvitamin D3 (VD3),
250nM phorbol ester (PMA) or VD3/PMA. Following 72 hours,
cell numbers were assessed using the cell count function of the
Quanta SC flow cytometer. Data shown are the mean ± SE of
cell counts from three independent experiments. (C) THP-1
monocytes (THP-1) cells were stimulated to differentiate in the
presence of dihydroxyvitamin D3 (VD3), phorbol ester (PMA) or
both (VD3/PMA) for 48 hours in 4 well chamber slides. Cell
nuclei were stained with acridine orange. Representative DIC
morphology images overlaid with fluorescence nuclear
morphology images of THP-1 cells or the resultant
differentiated cell are shown. Multinucleate cells, suggestive of
cell fusion, are shown (arrows). Scale bar = 16µm.
(TIF)
Figure S2.  Characterisation of HeLa cells transfected with
membrane associated CD14 constructs (WT and point
mutant).  (A) Monoclonal Ab 63D3 was tested for reactivity
against wild-type CD14 and a panel of point mutants. Anti-
human Fc immobilised soluble CD14-Fc fusion proteins were
probed by ELISA with mAb 63D3 and binding detected with
anti-mouse-HRP prior to developing with OPD substrate and
reading OD492nm. Data shown are mean ± SE of three
independent experiments. Statistical analyses indicate no
significant difference in response to any of the CD14 constructs
(ANOVA with Dunnett’s post-test). (B) HeLa cells were
transfected with pcDNA3/GFP. The fluorescence frequency
histogram shown reveals the representative bi-modal
expression pattern noted in all our HeLa cell studies. (C)
Regression analysis of 61D3 mapping studies on soluble CD14
constructs (WT and point mutants) and HeLa cell membrane
expressed constructs. Binding of 61D3 to sCD14 is plotted
against the mean fluorescence intensity of 61D3 stained HeLa
transfectants (all data from Figure 4). This analysis reveals a
strong correlation between 61D3 mapping on soluble and
membrane CD14 with a correlation coefficient (r) = 0.905.
(TIF)
Figure S3.  Monoclonal Ab MEM18 competes with 61D3 for
binding to CD14.  Anti-human Fc immobilised soluble WT
CD14-Fc fusion protein was probed by ELISA with mAb 61D3-
biotin and binding of the biotinylated mAb detected with
streptavidin-HRP prior to developing with OPD substrate and
reading OD492nm. The ability of unlabelled 61D3 (red bar) or
unlabelled MEM18 (blue bars, used at indicated
concentrations) to block binding of biotinylated 61D3 was
assessed. Data shown are mean ± SE of three independent
experiments. Statistical analyses used ANOVA with Dunnett’s
post-test to detect significant of differences compared to 61D3-
biotin alone (black bar).
(TIF)
Figure S4.  Assessment of LPS required to activate NFκB
inflammatory signalling.  HeLa cells were transfected with
both the luciferase NFκB reporter plasmid and a CD14WT
expression plasmid or ICAM-3 expression plasmid as a control
using TransIT LT-1. Expression was allowed to proceed for 24
hours prior to further analyses. Cells were treated with the
indicated concentrations of LPS for 5h prior to assessing
NFκB-mediated transcriptional activity with One-Glo Luciferase
assay system. Relative light units were quantified using a
microplate luminometer. The data shown is mean ± SE of three
independent experiments. Statistical analyses used ANOVA
with Tukey post-test. *P<0.05.
(TIF)
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